Cellectar Biosciences (CLRB) News Today $0.24 0.00 (-1.26%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB)December 20 at 2:49 AM | americanbankingnews.comRoth Capital Issues Positive Forecast for CLRB EarningsDecember 16, 2024 | americanbankingnews.comCellectar Biosciences' (CLRB) Market Perform Rating Reiterated at OppenheimerDecember 13, 2024 | americanbankingnews.comCellectar Biosciences downgraded to Perform from Outperform at OppenheimerDecember 12, 2024 | markets.businessinsider.comOppenheimer Downgrades Cellectar Biosciences (CLRB)December 12, 2024 | msn.comCellectar Biosciences trading resumesDecember 11, 2024 | markets.businessinsider.comCellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce CutDecember 11, 2024 | marketwatch.comCellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic OptionsDecember 11, 2024 | benzinga.comCellectar Biosciences trading halted, news pendingDecember 11, 2024 | markets.businessinsider.comCellectar stock plunges 50% post-market on restructuring newsDecember 11, 2024 | seekingalpha.comCellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate RestructuringDecember 10, 2024 | globenewswire.comCellectar Biosciences transferred with Buy rating at LadenburgDecember 6, 2024 | markets.businessinsider.comOppenheimer cuts Cellectar Biosciences stock target, outperform on Q3 financialsNovember 21, 2024 | uk.investing.comPositive Buy Rating on Cellectar Biosciences Driven by Promising Iopofosine-131 Results and Strategic AdvancementsNovember 21, 2024 | markets.businessinsider.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call TranscriptNovember 21, 2024 | msn.comRoth Capital Brokers Decrease Earnings Estimates for CLRBCellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Equities researchers at Roth Capital dropped their FY2024 EPS estimates for Cellectar Biosciences in a note issued to investors on Monday, November 18th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will pNovember 21, 2024 | marketbeat.comCellectar Biosciences price target lowered to $12 from $14 at OppenheimerNovember 20, 2024 | markets.businessinsider.comQ1 Earnings Estimate for CLRB Issued By Roth CapitalCellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Investment analysts at Roth Capital issued their Q1 2025 earnings per share estimates for shares of Cellectar Biosciences in a research note issued on Monday, November 18th. Roth Capital analyst J. Aschoff expects that the biopharmaceuticaNovember 20, 2024 | marketbeat.comOppenheimer Has Lowered Expectations for Cellectar Biosciences (NASDAQ:CLRB) Stock PriceOppenheimer lowered their price target on Cellectar Biosciences from $14.00 to $12.00 and set an "outperform" rating on the stock in a research note on Tuesday.November 19, 2024 | marketbeat.comCellectar Biosciences Reports Q3 2024 Financial ResultsNovember 19, 2024 | markets.businessinsider.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest UpdateCellectar Biosciences, Inc. (NASDAQ:CLRB - Get Free Report) saw a significant drop in short interest in October. As of October 31st, there was short interest totalling 1,840,000 shares, a drop of 6.1% from the October 15th total of 1,960,000 shares. Approximately 4.7% of the company's shares are short sold. Based on an average daily volume of 245,400 shares, the days-to-cover ratio is presently 7.5 days.November 18, 2024 | marketbeat.comCellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate UpdateNovember 18, 2024 | globenewswire.comCellectar Biosciences signs strategic supply agreement with NorthStarNovember 14, 2024 | markets.businessinsider.comCellectar Biosciences, Inc.: Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225November 14, 2024 | finanznachrichten.deCellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225November 14, 2024 | globenewswire.comCellectar Biosciences (CLRB) to Release Earnings on MondayCellectar Biosciences (NASDAQ:CLRB) will be releasing earnings before the market opens on Monday, November 18, Zacks reports.November 12, 2024 | marketbeat.comCellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of CancerNovember 12, 2024 | globenewswire.comCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024November 11, 2024 | globenewswire.comCellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024November 7, 2024 | globenewswire.comRosalind Advisors Inc. Has $7.86 Million Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB)Rosalind Advisors Inc. lifted its holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) by 35.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,671,550 shares of the biopharmaceutical company's stock after buying an aNovember 6, 2024 | marketbeat.comCellectar Biosciences regains compliance with NasdaqNovember 1, 2024 | markets.businessinsider.comCellectar Biosciences Announces Compliance Regarding Filing of Form 10-QNovember 1, 2024 | globenewswire.comCellectar Biosciences (NASDAQ:CLRB) Stock Passes Above Fifty Day Moving Average - Here's What HappenedCellectar Biosciences (NASDAQ:CLRB) Stock Price Crosses Above 50 Day Moving Average - Here's WhyOctober 23, 2024 | marketbeat.comCellectar Biosciences (NASDAQ:CLRB) Stock Quotes, Forecast and News SummaryOctober 20, 2024 | benzinga.comCellectar Biosciences, Inc. (NASDAQ:CLRB) Sees Large Increase in Short InterestCellectar Biosciences, Inc. (NASDAQ:CLRB - Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 2,200,000 shares, a growth of 35.8% from the September 15th total of 1,620,000 shares. Approximately 6.3% of the shares of the company are sold short. Based on an average daily trading volume, of 479,000 shares, the days-to-cover ratio is currently 4.6 days.October 15, 2024 | marketbeat.comCellectar Biosciences (NASDAQ:CLRB) Given Outperform Rating at OppenheimerOppenheimer reiterated an "outperform" rating and issued a $14.00 price target on shares of Cellectar Biosciences in a report on Friday.October 11, 2024 | marketbeat.comCellectar Biosciences (NASDAQ:CLRB) Upgraded at StockNews.comStockNews.com upgraded Cellectar Biosciences to a "sell" rating in a research report on Thursday.September 26, 2024 | marketbeat.comCellectar Biosciences (NASDAQ:CLRB) Stock Passes Below 200 Day Moving Average of $2.99Cellectar Biosciences (NASDAQ:CLRB) Stock Passes Below 200-Day Moving Average of $2.99September 6, 2024 | marketbeat.comIopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's MacroglobulinemiaAugust 26, 2024 | stockhouse.comIopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's MacroglobulinemiaAugust 26, 2024 | globenewswire.comCellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from NasdaqAugust 23, 2024 | globenewswire.comCLRB Sep 2024 5.000 callAugust 18, 2024 | ca.finance.yahoo.comVanguard Group Inc. Has $4.74 Million Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB)Vanguard Group Inc. boosted its holdings in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) by 146.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,191,081 shares of the biopharmaceutical companyAugust 18, 2024 | marketbeat.comCLRB Sep 2024 2.500 callAugust 17, 2024 | ca.finance.yahoo.comOppenheimer Keeps Their Buy Rating on Cellectar Biosciences (CLRB)August 15, 2024 | markets.businessinsider.comEquities Analysts Set Expectations for Cellectar Biosciences, Inc.'s Q3 2024 Earnings (NASDAQ:CLRB)Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Stock analysts at Roth Capital decreased their Q3 2024 earnings per share estimates for Cellectar Biosciences in a report released on Tuesday, August 13th. Roth Capital analyst J. Aschoff now forecasts that the biopharmaceutical company wiAugust 15, 2024 | marketbeat.comCellectar Biosciences, Inc. to Post FY2027 Earnings of $1.94 Per Share, Roth Capital Forecasts (NASDAQ:CLRB)Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Equities research analysts at Roth Capital reduced their FY2027 earnings estimates for shares of Cellectar Biosciences in a research report issued on Tuesday, August 13th. Roth Capital analyst J. Aschoff now forecasts that the biopharmaceuAugust 14, 2024 | marketbeat.comCellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate UpdateAugust 13, 2024 | globenewswire.comCellectar Biosciences Q2 2024 Earnings PreviewAugust 12, 2024 | msn.comCellectar Biosciences (CLRB) Set to Announce Quarterly Earnings on TuesdayCellectar Biosciences (NASDAQ:CLRB) will be releasing earnings before the market opens on Tuesday, August 13, Zacks reports.August 9, 2024 | marketbeat.com Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this coin BEFORE Inauguration Day … (Ad)Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office. This could be his favorite coin. CLRB Media Mentions By Week CLRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLRB News Sentiment▼0.520.61▲Average Medical News Sentiment CLRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLRB Articles This Week▼52▲CLRB Articles Average Week Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACHL News CLNN News DTIL News LEXX News VYNE News ATNM News OCX News LTRN News ELEV News LUMO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLRB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
